Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (114)	2/11/2000 12:37:00 PM
From: aknahow	Read Replies (1) \| Respond to of 362

Nice article on Titan Corp. Feb. 11 IBD Page A 9. Not online. Or, I could not find it on Investors (keyword) Business Daily site. Novartis is fully funding Titans efforts to bring Zomatril ....to market. If the compound wins approval, Titan will receive 8% of its' first $200 million in sales. Above that mark it gets 10%, all of which would be profit. Two points, FIRST. FULL DISCLOSURE OF THE ROYALTY! SECOND. THE ROYALTY GOES UP AS SALES GO UP!